IN RE: SUBOXONE (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE) ANTITRUST LITIGATION
Case Number:
2:13-md-02445
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
-
September 26, 2022
Two Funds Seek Invidior Antitrust Docs In Securities Case
Two municipal retirement funds asked a Pennsylvania federal court for permission to intervene in a case accusing pharmaceutical firm Indivior PLC of monopolizing the market for the opioid addiction treatment suboxone so that the funds can obtain material for use in a securities case over the alleged conduct.
-
August 22, 2022
Indivior Loses Bid For Early Win In 'Product Hop' MDL
A Pennsylvania federal judge on Monday refused to hand Indivior an early win in sprawling antitrust litigation alleging the drugmaker monopolized the market for the opioid addiction treatment suboxone, ruling that the claims rest on issues of fact that belong before a jury.
-
February 02, 2022
Indivior Again Loses Bid To DQ Bankrupt Suboxone Plaintiff
A Pennsylvania federal judge on Wednesday again rejected a move to disqualify a named plaintiff in the massive antitrust litigation accusing drugmaker Indivior PLC of monopolizing the market for the opioid addiction treatment suboxone, saying the plaintiff's bankruptcy doesn't mean it can't serve a leadership role in the litigation.
-
May 04, 2021
Defunct Wholesaler Fights Renewed DQ Bid In Suboxone Case
Rochester Drug Co-Operative Inc. has urged a Pennsylvania federal judge to once again reject arguments that the company's ongoing bankruptcy meant that it could not continue serving as class representative in a massive antitrust suit accusing drugmaker Indivior PLC of scheming to maintain its monopoly on the opioid addiction treatment Suboxone.
-
April 16, 2021
Late Bid For New Suboxone Antitrust Complaint Falls Flat
A Pennsylvania federal judge on Thursday shot down a bid by direct purchasers in an antitrust case against Indivior Inc. to amend their complaint to target several company affiliates they accuse of siphoning money from Indivior to help the drugmaker avoid a potential judgment over its alleged monopolization.
-
January 22, 2021
Judge Won't DQ Class Rep In Suboxone 'Hopping' Suit
A Pennsylvania federal judge rejected Indivior's bid to disqualify a class representative in a massive antitrust suit accusing the drugmaker of scheming to change the form of opioid addiction treatment Suboxone solely to keep its grip on exclusivity.
-
September 18, 2020
Wholesaler Fights To Stay Suboxone Product-Hop Class Rep
Drug wholesaler Rochester Drug Co-Operative is defending its role as a class representative for Suboxone buyers suing Indivior Inc. over an alleged product-hop scheme in Pennsylvania federal court, arguing that neither its pending bankruptcy nor past conduct should disqualify it.
-
September 08, 2020
Indivior Wants Class Rep DQ'd In Suboxone Product-Hop Suit
Indivior Inc. has asked a Pennsylvania federal court to disqualify bankrupt drug wholesaler Rochester Drug Co-Operative from representing a class suing over a product hop scheme that allegedly inflated the price of the opioid addiction treatment Suboxone.
-
September 27, 2019
2 Classes Certified In Suboxone Product-Hop Suit
A Pennsylvania federal judge on Friday certified a class of direct purchasers of Suboxone as well as a class of end payors in multidistrict litigation over an alleged product-hopping scheme by Indivior PLC to block generic versions of the opioid treatment drug from coming to market.
-
September 03, 2019
Practicality Key In Suboxone Class Cert. Bid, Judge Suggests
A Pennsylvania federal judge said during a hearing Tuesday that the difficulties of managing a trial with dozens of potential plaintiffs may warrant class certification in multidistrict litigation over an alleged product-hopping scheme by Indivior PLC to block generic versions of the opioid treatment drug Suboxone from coming to market.